Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Cocaine-Related Disorders

ClinicalTrials.gov lists 416 trials for Cocaine-Related Disorders or a narrower condition beneath it. National Institute on Drug Abuse (NIDA) has the most among industry and government lead sponsors, with 105.

MeSH D019970 Chemically-Induced Disorders C25 F03
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 89 Phase 1/2 Phase 1/2 13 Phase 2 Phase 2 174 Phase 2/3 Phase 2/3 12 Phase 3 Phase 3 13 Phase 4 Phase 4 16 Not applicable Not applicable 69 Observational Observational 30 Phase 1 Phase 1 89 Phase 1/2 Phase 1/2 13 Phase 2 Phase 2 174 Phase 2/3 Phase 2/3 12 Phase 3 Phase 3 13 Phase 4 Phase 4 16 Not applicable Not applicable 69 Observational Observational 30

Trials per phase

416 of the 416 trials are tagged with Cocaine-Related Disorders itself; the rest are tagged with a narrower condition beneath it.

Get the Cocaine-Related Disorders report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Cocaine-Related Disorders trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 29

1990: 3 trials (Phase 2 3) 1991: 2 trials (Phase 2 1, Phase 1 1) 1992: 3 trials (Phase 2 3) 1993: 1 trials (Observational 1) 1994: 14 trials (Phase 2 11, Phase 1 3) 1995: 9 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 5) 1996: 17 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 7, Phase 1 7) 1997: 14 trials (Phase 4 1, Phase 2 10, Phase 1 3) 1998: 8 trials (Observational 1, Phase 3 2, Phase 2/3 1, Phase 2 3, Phase 1 1) 1999: 7 trials (Phase 3 1, Phase 2 5, Phase 1 1) 2000: 2 trials (Phase 2 2) 2001: 15 trials (Not applicable 2, Phase 3 1, Phase 2 8, Phase 1 4) 2002: 6 trials (Not applicable 2, Phase 2 1, Phase 1 3) 2003: 16 trials (Observational 2, Not applicable 3, Phase 4 3, Phase 2 5, Phase 1 3) 2004: 19 trials (Not applicable 2, Phase 2 9, Phase 1 8) 2005: 20 trials (Observational 4, Not applicable 3, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 7, Phase 1 3) 2006: 18 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 2 10, Phase 1/2 2, Phase 1 2) 2007: 29 trials (Observational 3, Not applicable 8, Phase 3 1, Phase 2/3 1, Phase 2 13, Phase 1 3) 2008: 19 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 2/3 2, Phase 2 5, Phase 1/2 3, Phase 1 5) 2009: 19 trials (Observational 6, Not applicable 2, Phase 4 1, Phase 3 1, Phase 2 7, Phase 1 2) 2010: 24 trials (Observational 1, Not applicable 2, Phase 3 2, Phase 2/3 1, Phase 2 12, Phase 1/2 1, Phase 1 5) 2011: 23 trials (Observational 1, Not applicable 5, Phase 3 1, Phase 2/3 2, Phase 2 7, Phase 1/2 3, Phase 1 4) 2012: 14 trials (Observational 1, Not applicable 7, Phase 2 3, Phase 1/2 1, Phase 1 2) 2013: 11 trials (Observational 1, Phase 4 1, Phase 2/3 1, Phase 2 7, Phase 1 1) 2014: 18 trials (Not applicable 4, Phase 4 1, Phase 2/3 2, Phase 2 4, Phase 1/2 2, Phase 1 5) 2015: 8 trials (Observational 2, Phase 4 1, Phase 2/3 1, Phase 2 1, Phase 1 3) 2016: 11 trials (Observational 2, Not applicable 1, Phase 2 4, Phase 1 4) 2017: 10 trials (Not applicable 6, Phase 4 1, Phase 2 3) 2018: 6 trials (Not applicable 1, Phase 2 1, Phase 1/2 1, Phase 1 3) 2019: 7 trials (Not applicable 4, Phase 2 1, Phase 1 2) 2020: 4 trials (Not applicable 1, Phase 2 2, Phase 1 1) 2021: 3 trials (Not applicable 1, Phase 2 1, Phase 1 1) 2022: 2 trials (Not applicable 2) 2023: 6 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 2 2) 2024: 3 trials (Phase 2 2, Phase 1 1) 2025: 2 trials (Not applicable 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 4
2025 2
2024 3
2023 6
2022 2
2021 3
2020 4
2019 7
2018 6
2017 10

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

No forecast is made for this condition: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.

Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 38 months across 299 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Cocaine-Related Disorders trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 89
Phase 1/2 13
Phase 2 174
Phase 2/3 12
Phase 3 13
Phase 4 16
Not applicable 69
Observational 30

How many Cocaine-Related Disorders trials are recruiting? (8)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 1
Recruiting 8
Active, not recruiting 2
Completed 328
Suspended 1

Showing 5 of 8 statuses.

Start your 14-day trial Email me all 8 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Cocaine-Related Disorders trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute on Drug Abuse (NIDA) 105

Which drugs are being tested for Cocaine-Related Disorders? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Modafinil 18
Cocaine 17
Disulfiram 11
Dextroamphetamine 11
METHYLPHENIDATE 9

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
IM naltrexone 10
IR Risperidone 9
N Acetylcysteine 7
Propranolol PO 6
Topiramate IR 5

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Cocaine-Related Disorders trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Hospitalization 29 3
Substance Use Hospitalization 23 1
Other hospitalizations 18 1
Exacerbation of cocaine and alcohol 15 1
Inpatient Substance Use Treatment Hospitalization 13 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Cocaine-Related Disorders? (452)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Absence of Evidence for Sustained Effects of Daily Cannabidiol Administration on Anandamide Plasma Concentration in Individuals with Cocaine Use Disorder: Exploratory Findings from a Randomized Controlled Trial. Cannabis and cannabinoid research 2025 Yes
Undervaluing nondrug rewards or overvaluing cocaine? Cocaine demand relates to cocaine use severity more strongly than anhedonia in individuals with cocaine use disorder. Experimental and clinical psychopharmacology 2025 Yes
The role of Iowa gambling task performance in response to citalopram treatment for cocaine use disorder. The American journal of drug and alcohol abuse 2025 Yes
Repetitive transcranial magnetic stimulation for stimulant use disorders (STIMULUS): protocol for a multi-site, double-blind, randomized controlled trial. Addiction science & clinical practice 2025 Yes
Randomized, placebo-controlled trial of injectable extended-release naltrexone and injectable extended-release buprenorphine for cocaine use disorder (CURB-2): Study rationale and design. Contemporary clinical trials 2025 Yes

Showing 5 of 452 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages